Immunohistochemical study of differential expressions of BR3 (BAFF-R) in malignant lymphomas of oral and maxillofacial regions

OKADA Y; OKADA Y; OKADA Y; OHKUBO Y; OHKUBO Y; KANRI Y; KANRI Y; ONO J; ISHIGURO H; MORIDE M; HASEGAWA H

Art

J-GLOBAL ID：201702238460637493 Reference number：17A0654983

Immunohistochemical study of differential expressions of BR3 (BAFF-R) in malignant lymphomas of oral and maxillofacial regions

口腔顎顔面領域の悪性リンパ腫におけるBR3(BAFF-R)の異なった発現の免疫組織化学的研究

Publisher site {{ this.onShowPLink() }} Copy service
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0654983&from=J-GLOBAL&jstjournalNo=L7996A") }}

Author (11)： , , , , , , , , , ,
Material：
Volume： 7 Issue： 1 Page： 16-22 Publication year： Mar. 31, 2015
JST Material Number： L7996A ISSN： 1883-3888 Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0654983&from=J-GLOBAL&jstjournalNo=L7996A") }}

Blood cell tumors(=neoplasms) , Tumors(=neoplasms)of tooth and mouth(=oral cavity) , Diagnosis of tumors(=neoplasms) , Pathological tests

Reference (32)：

Kemp S, Gallagher G, Kabani S, Noonan V, O'hara C: Oral non-Hodgkin's lymphoma, review of the literature and World Health Organization classification with reference to 40 cases, Oral Surg Oral Med Oral Pathol Oral Radiol Oral Endod, 105: 194-201, 2008
Sato Y, Onishi N, Morito T, Takata K, Mizobuchi K, Nagatsuka H, Ichimura K, Tanaka T, Tamura M, Yoshino T: Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype, Cancer Sci, 100: 42-46, 2009
Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ: The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia, Blood, 97: 3370-3379, 2001
Coiffier B, Lepage E, Briëre J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C: Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346: 235-242, 2002
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, 106: 3725-3732, 2005

ｍore...

, , , , ,

Return to Previous Page